Back to skills
SKILL.md
Alert System
ASecurityAutomated alert system for key events in drug discovery. Use for tracking competitor milestones, clinical trial updates, regulatory decisions, and publications of interest. Keywords: alerts, monitoring, tracking, notifications, competitive intelligence
- 18 stars
- 0 votes
- 0 copies
- 3 views
- Added February 7, 2026
Works with
Security analysis
96/100- Installs packages at runtime which could introduce malicious dependencies
Pro scans all 3 files and shows the line behind each finding
npx -y skills add huifer/drug-discovery-skills --skill alert-system --agent claude-codeAre you the author of Alert System?
Add the live security badge to your README. It updates with every re-scan.
[](https://www.skillsdirectory.com/skills/huifer-alert-system)---
name: alert-system
description: |
Automated alert system for key events in drug discovery. Use for tracking
competitor milestones, clinical trial updates, regulatory decisions, and
publications of interest.
Keywords: alerts, monitoring, tracking, notifications, competitive intelligence
category: Intelligence
tags: [alerts, monitoring, notifications, tracking]
version: 1.0.0
author: Drug Discovery Team
dependencies:
- clinicaltrials-api
- fda-api
- pubmed-api
---
# Alert System Skill
Automated monitoring and alerting for drug discovery intelligence.
## Quick Start
```
/alerts --create --target "EGFR inhibitors" --events clinical,fda
/alerts --list
/alerts --check my-alert
```
## What's Included
| Alert Type | Description | Sources |
|------------|-------------|---------|
| Clinical Updates | Trial status changes | ClinicalTrials.gov |
| Regulatory | FDA/EMA decisions | FDA, EMA |
| Publications | New papers on target | PubMed |
| Competitor | Pipeline updates | Press releases |
| Patent | New patent filings | USPTO, EPO |
| Conference | Meeting abstracts | ASCO, ESMO |
## Alert Configuration
```yaml
name: EGFR Competitive Alerts
description: Monitor EGFR inhibitor landscape
targets:
- EGFR
- Exon 19 deletion
- T790M
- C797S
competitors:
- AstraZeneca
- Johnson & Johnson
- Roche
events:
- clinical_trial_updates
- regulatory_approvals
- publications
- patent_filings
filters:
phase: [2, 3]
countries: [US, EU, CN, JP]
minimum_significance: high
notifications:
email: user@example.com
frequency: weekly
format: summary
```
## Output Structure
```markdown
# Alert Report: EGFR Landscape (Weekly)
## Summary
| Alert Type | New | Total |
|------------|-----|-------|
| Clinical Updates | 3 | 127 |
| Publications | 12 | 456 |
| Regulatory | 1 | 23 |
| Patent Filings | 5 | 89 |
## Clinical Trial Updates
### New Trials
| NCT ID | Sponsor | Phase | Indication | Status |
|--------|---------|-------|------------|--------|
| NCT01234567 | AstraZeneca | 3 | NSCLC | Recruiting |
| NCT01234568 | Johnson & Johnson | 2 | NSCLC | Not recruiting |
### Status Changes
| NCT ID | Previous | Current | Date |
|--------|----------|---------|------|
| NCT07890123 | Recruiting | Active, not recruiting | 2024-12-10 |
## Key Publications
1. **Fourth-generation EGFR inhibitors targeting C797S**
- Journal: Nature Cancer
- Date: 2024-12-08
- Authors: Zhang et al.
- Impact: Novel scaffold for resistance
2. **Combination therapy: EGFR + MET inhibition**
- Journal: Lancet Oncology
- Date: 2024-12-05
- Authors: Smith et al.
- Impact: Positive Phase 2 results
## Regulatory Updates
### FDA Actions
| Date | Sponsor | Action | Drug |
|------|---------|--------|------|
| 2024-12-12 | AstraZeneca | Approval | Tagrisso (adjuvant) |
## Patent Filings
### New Patents
| Date | Assignee | Title | Patent No. |
|------|----------|-------|------------|
| 2024-12-10 | Merck | EGFR C797S inhibitors | US2024/XXX |
| 2024-12-08 | Roche | Antibody-drug conjugate | EPXXX |
## Recommendations
**Action Items**:
1. Review new C797S inhibitor paper - assess differentiation
2. Monitor AstraZeneca adjuvant approval impact
3. Investigate Merck's new patent - potential FTO issue
```
## Event Types
| Event | Description | Priority |
|-------|-------------|----------|
| Clinical trial starts | New trial initiated | Medium |
| Clinical trial completes | Primary endpoint reached | High |
| Regulatory approval | Drug approval | High |
| Regulatory rejection | CRL, rejection | High |
| Key publication | High-impact paper | Medium |
| Competitor deal | M&A, licensing | High |
| Patent granted | New patent issued | Medium |
| Patent expiry | Patent expires | Low |
## Running Scripts
```bash
# Create new alert
python scripts/alert_system.py --create my-alert --target "EGFR"
# Check for updates
python scripts/alert_system.py --check my-alert
# List all alerts
python scripts/alert_system.py --list
# Export alert history
python scripts/alert_system.py --export my-alert --format csv
```
## Requirements
```bash
pip install requests schedule
# For persistence
pip install sqlalchemy
```
## Reference
- [reference/alert-types.md](reference/alert-types.md) - Alert type reference
- [reference/data-sources.md](reference/data-sources.md) - Data source configuration
- [reference/notifications.md](reference/notifications.md) - Notification setup
## Best Practices
1. **Set specific targets**: Narrower = fewer false positives
2. **Use appropriate frequency**: Daily for high-priority, weekly for others
3. **Review regularly**: Alerts need human interpretation
4. **Adjust filters**: Refine based on signal-to-noise
5. **Document actions**: Track alert-driven decisions
## Common Pitfalls
| Pitfall | Solution |
|---------|----------|
| Too many alerts | Narrow target/event filters |
| False positives | Add confidence filters |
| Alert fatigue | Adjust frequency and thresholds |
| Missing context | Include summary with links |
| No action tracking | Document response to alerts |
## Alert Frequency Guidelines
| Priority | Check Frequency | Notification |
|----------|-----------------|--------------|
| Critical | Hourly | Immediate |
| High | Daily | Daily digest |
| Medium | Weekly | Weekly summary |
| Low | Monthly | Monthly report |
Files in this skill
- SKILL.md
- reference/alert-types.md
- scripts/alert_system.py
Attribution
Comments
Loading comments…
Newsletter
Get the weekly list of safe new skills, and the ones we pulled.